Mass balance, excretion, and pharmacokinetics of a single oral dose of [14C]pixavir marboxil in healthy Chinese male participants
Frontiers in Pharmacology · 11.08.2026 · 17
DOI: 10.3389/fphar.2026.1905373 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 11.08.2026. Verfasst von Chunyang Zhao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Drug Clinical Trial Center, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Objective Cap-dependent endonuclease (CEN) inhibitors are a promising novel class of antiviral agents for influenza treatment. This phase I study aimed to evaluate the mass balance, excretion pathways, and pharmacokinetics of pixavir marboxil (TG-1000), a novel CEN inhibitor prodrug, in healthy humans.
Methods
Six healthy Chinese male participants received a single oral dose of 40 mg (100 μCi) [ 14 C]pixavir marboxil. Blood, urine, and fecal samples were collected at predefined intervals up to 384 h post-dose. Total radioactivity was determined using oxidative combustion and liquid scintillation counting. Pharmacokinetic parameters were calculated using non-compartmental analysis, and metabolite profiling was conducted using high-performance liquid chromatography coupled with radiochemical detection and high-resolution mass spectrometry.
Results
Intact pixavir marboxil was undetectable in plasma. Systemic exposure primarily consisted of its active metabolite, pixavir (TG-0527), and a subsequent glucuronide conjugate, TG-0600771. The geometric mean areas under the curve ( A U C 0 − ∞ ) for total radioactivity, pixavir, and TG-0600771 in six participants were 4,220 hng Eq./mL, 2,490 hng/mL, and 981 hng/mL, respectively. The administered radioactive dose demonstrated a mean cumulative recovery of 91.29%, with 85.62% recovered in feces and 5.68% in urine. Metabolite profiling identified pixavir and TG-0600771 as the major metabolites, with no major cytochrome P450 (CYP)-mediated oxidative metabolites observed in plasma. The single dose of [ 14 C]pixavir marboxil was safe and well-tolerated.
Conclusion
Pixavir marboxil exhibits a favorable pharmacokinetic profile characterized by rapid systemic conversion to its active metabolite, CYP-independent metabolism, and predominantly non-renal clearance. These favorable pharmacokinetic characteristics support a well-characterized disposition profile with limited reliance on CYP-mediated metabolism and renal excretion of active pixavir. Trial Registration This study was registered with Drug Clinical Trial Registration and Information Disclosure Platform, National Medical Products Administration (NMPA), number CTR20231822 ( http://www.chinadrugtrials.org.cn/ ).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Drug Clinical Trial Center, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China.
- Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Shanghai, China.
- Joincare Pharmaceutical Group Industry Co., Ltd., Shenzhen, Guangdong, China.
- TaiGen Biotechnology Co., Ltd., Taipei, Taiwan.
Zitieren
APA
Zhao, C., Yang, Y., Liu, G., Qian, L., Liu, Y., Tsai, C. Y., Chang, L. W., Chen, Q., Qian, H., Jia, J., & Liu, Y. (2026). Mass balance, excretion, and pharmacokinetics of a single oral dose of [14C]pixavir marboxil in healthy Chinese male participants. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1905373
Vancouver
Zhao C, Yang Y, Liu G, Qian L, Liu Y, Tsai CY, et al. Mass balance, excretion, and pharmacokinetics of a single oral dose of [14C]pixavir marboxil in healthy Chinese male participants. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1905373
BibTeX
@article{Zhao2026,
author = {Zhao, Chunyang and Yang, Ying and Liu, Gangyi and Qian, Lin and Liu, Yun and Tsai, Cheng-Yuan and Chang, Li-Wen and Chen, Qian and Qian, Hongjie and Jia, Jingying and Liu, Yanmei},
title = {Mass balance, excretion, and pharmacokinetics of a single oral dose of [14C]pixavir marboxil in healthy Chinese male participants},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1905373}
}
EUVIMED